What's Going On With Moderna Stock Friday?
What's Going On With Moderna Stock Friday?
Moderna, Inc. (NASDAQ:MRNA) stock is trending on Friday. The company announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion for its RSV vaccine.
Modern,Inc.(纳斯达克: MRNA)股票在周五上涨。该公司宣布,欧洲药品管理局的人用药品委员会已经通过了对其RSV疫苗的积极意见。
The Details: The RSV vaccine, mRNA-1345, is designed to protect adults aged 60 and older from respiratory disease caused by the RSV infection. As a result, the European Commission will authorize the vaccine.
细节:RSV疫苗mRNA-1345旨在保护60岁及以上的成年人免受RSV感染引起的呼吸道疾病。因此,欧洲委员会将批准该疫苗。
The positive finding is based on data from the Phase 3 clinical trial ConquerRSV. The trial included 37,000 adults, aged 60 or older, and found an efficacy rate of 83.7% with 3.7 months of median follow-up against lower respiratory tract disease caused by RSV. The study also found sustained vaccine efficacy of 63.3% at a median follow up rate of 8.6 months.
该积极结果基于阶段3临床试验ConquerRSV的数据。试验涵盖了37,000名60岁或以上的成年人,并发现在对抗由RSV引起的下呼吸道疾病时,中位随访时间为3.7个月,有效率达到83.7%。该研究还发现,8.6个月的中位随访时间保持了63.3%的疫苗有效性。
"mRESVIA safeguards older adults against severe RSV outcomes and is uniquely offered in a pre-filled syringe to enhance ease of administration, which can save healthcare professionals time and reduce administrative errors," said Stéphane Bancel, CEO of Moderna.
“mRESVIA可以保护老年人免受RSV严重后果,独特的预装注射器可提高管理的便利性,节省医疗保健专业人员的时间并减少行政错误,”Moderna首席执行官Stéphane Bancel说。
The United States Food and Drug Administration approved the vaccine in May 2024 for adults 60 and older.
美国食品和药品管理局于2024年5月批准该疫苗用于60岁及以上的成年人。
Analyst Changes: Several analysts have issued price target adjustments recently.
分析师改变看法:几名分析师最近发表了价格目标的调整。
- On Friday, Needham analyst Joseph Stringer reiterated Moderna with a Hold.
- On Thursday, Evercore ISI Group analyst Cory Kasimov maintained Moderna with a In-Line and maintained a $120 price target.
- Also on Thursday, Piper Sandler analyst Edward Tenthoff reiterated Moderna with a Overweight and maintained a $214 price target.
- 周五,Needham分析师Joseph Stringer重申了对Moderna的持有意见。
- 周四,Evercore ISI Group分析师Cory Kasimov维持了对Moderna的内部意见,并维持了120美元的价格目标。
- 同样是在周四,Piper Sandler分析师Edward Tenthoff重申了对Moderna的超配评级,并维持了214美元的价格目标。
FDA Rejects Rocket Pharmaceuticals' Gene Therapy For Rare Immune Disorder, Asks For More Data, Stock Slides
FDA拒绝了Rocket Pharmaceuticals的罕见免疫障碍基因治疗方案,要求更多的数据,股票下滑。
MRNA Price Action: At the time of writing, Moderna shares are trading 1.96% lower at $118.80 per data from Benzinga Pro.
MRNA价格行情:截至撰写本文时,根据Benzinga Pro提供的数据,Moderna股票下跌1.96%,报118.80美元。
Image: Lutsenko_Oleksandr on Shutterstock
图片:Shutterstock的Lutsenko_Oleksandr